Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617

This retrospective study evaluated the prognostic value of baseline systemic inflammatory markers in 163 patients with metastatic castration-resistant prostate cancer treated with lutetium-177 PSMA-617 at Emory Winship Cancer Institute, a racially diverse cohort where 43.6% of patients identified as Black. Elevated neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, pan-immune-inflammation value, and systemic immune-inflammation index, as well as reduced hemoglobin-to-platelet ratio, were each independently associated with shortened overall survival, with hazard ratios ranging from 2.08 to 2.86. Higher levels of several of these markers were also independently prognostic of shortened progression-free survival.

These findings suggest that readily available, low-cost inflammatory markers drawn from routine bloodwork may offer clinicians a practical tool for risk stratification and treatment planning in patients receiving this increasingly important therapy. As lutetium-177 PSMA-617 becomes more widely adopted across diverse patient populations, identifying reliable biomarkers that can predict outcomes and guide personalized care decisions becomes a clinical priority, and this study advances that effort with real-world data from one of the more racially diverse cohorts reported in this disease setting.